|

Pembrolizumab 200 mg Q3W or 400 mg Q6W Clinical Trials

1 actively recruiting trial

Pipeline

Phase 3: 1

Top Sponsors

  • Gustave Roussy, Cancer Campus, Grand Paris1

Indications

  • Metastatic Non-squamous Lung Cancer1
  • Lung Cancer1
  • Cancer1

Other1 trial

Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority Study
Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.